Qure N.V. QURE surged 109.7% after it announced reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130, a one-time administered investigational gene therapy, which is being developed to treat Huntington’s disease.

The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an accelerated approval application.